Premium
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
Author(s) -
Tarhini Ahmad A.,
Rafique Imran,
Floros Theofanis,
Tran Phu,
Gooding William E.,
Villaruz Liza C.,
Burns Timothy F.,
Friedland David M.,
Petro Daniel P.,
Farooqui Mariya,
GomezGarcia Jose,
GaitherDavis Autumn,
Dacic Sanja,
Argiris Athanassios,
Socinski Mark A,
Stabile Laura P.,
Siegfried Jill M.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30717
Subject(s) - medicine , erlotinib , epidermal growth factor receptor , kras , hepatocyte growth factor , gastroenterology , phases of clinical research , lung cancer , oncology , gemcitabine , cancer , erlotinib hydrochloride , chemotherapy , receptor , colorectal cancer
BACKGROUND Activation of the mesenchymal‐epidermal transition factor (MET) tyrosine kinase and its ligand, hepatocyte growth factor (HGF), is implicated in resistance to epidermal growth factor receptor (EGFR) inhibitors. In this phase 1/2 trial, rilotumumab (an anti‐HGF antibody) combined with erlotinib was evaluated in patients with metastatic, previously treated non–small cell lung cancer. METHODS In phase 1, a dose de‐escalation design was adopted with rilotumumab starting at 15 mg/kg intravenously every 3 weeks and oral erlotinib 150 mg daily. In phase 2, the disease control rate (DCR) (according to Response Evaluation Criteria in Solid Tumors) of the combination was evaluated using a Simon 2‐stage design. The biomarkers examined included 10 plasma‐circulating molecules associated with the EGFR and MET pathways. RESULTS Without indications for de‐escalation, the recommended phase 2 dose was dose level 0. Overall, 45 response‐evaluable patients were enrolled (13 with squamous carcinoma, 32 with adenocarcinoma; 2 had confirmed EGFR mutations, 33 had confirmed wild‐type [WT] EGFR, and 7 had KRAS mutations). The DCR for all patients was 60% (90% confidence interval [CI], 47.1%‐71.3%). Median progression‐free survival was 2.6 months (90% CI, 1.4‐2.7 months), and median overall survival was 6.6 months (90% CI, 5.6‐8.9 months). Among patients with WT EGFR, the DCR was 60.6% (90% CI, 46.3%‐73.3%), median progression‐free survival was 2.6 months (90% CI, 1.4‐2.7 months), and median overall survival was 7.0 months (90% CI, 5.6‐13.4 months). Elevated baseline levels of neuregulin 1 were associated with longer progression‐free survival (hazard ratio, 0.41; 95% CI, 0.19‐0.87), whereas elevated amphiregulin levels were associated with more rapid progression (hazard ratio, 2.14; 95% CI, 1.48‐3.08). CONCLUSIONS Combined rilotumumab and erlotinib had an acceptable safety profile, and the DCR met the prespecified criteria for success. In the EGFR WT group, the DCR exceeded published reports for erlotinib alone. High circulating levels of neuregulin 1 may indicate sensitivity to this combination. Cancer 2017;123:2936–44. © 2017 American Cancer Society .